Johnson & Johnson on Tuesday reported third-quarter results which were highlighted by strong pharmaceutical sales. According to an earnings statement, the company reported net earnings of $4.3 billion, or $1.53 earnings per share, on revenue of $17.8 billion. Alex Gorsky, Chairman and CEO of Johnson & Johnson, said in a statement that the results reflect…
Medisafe Announces New Adherence Solution for Pharma
Medisafe, a provider of medication management platform with three million patient and caregiver registered users, announced today the official launch of Medisafe for Pharma. Following a series of successful pilots and engagements over the past year and a half, Medisafe has now bundled a number of services into a software license that helps pharmaceutical companies…
Report: ‘Cosmeceuticals’ Market Expected To Skyrocket In Coming Years
The market for cosmetics provided by physicians, also called cosmeceuticals, is execpted to take off in the next few years. According to a new report by Transparency Market Research (TMR), the market is currently undergoing a paradigm shift with a large pool of skincare specialists, dermatologists, and trichologists emerging as entrepreneurs. However, the top three…
Actavis Moves to Adopt New ‘Allergan’ Corporate Name
Actavis, previously Watson Pharmaceuticals, today announced that it will adopt a new corporate name – Allergan – following the anticipated successful completion of the acquisition of Allergan, Inc. In a statement, the Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will…
EMA Accepts Pfizer’s MAA for New Vaccine
Pfizer Inc. today announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Trumenb (Meningococcal Group B Vaccine) for review. Trumenba has been developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older. In a statement the company…
Market for Preventative RSV Therapies Sees Modest Growth
The market for preventive therapies to treat RSV Infections will experience modest annual growth over the 2010-2020 forecast period, as market size increase from $148.9 million to 777.49 million in European five countries, according to a new report from Research and Markets. Respiratory syncytial virus (RSV) is a virus that causes infections of the lungs…